Compare FRST & ABEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FRST | ABEO |
|---|---|---|
| Founded | 2004 | 1974 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 261.7M | 281.0M |
| IPO Year | 2006 | 1980 |
| Metric | FRST | ABEO |
|---|---|---|
| Price | $13.30 | $5.09 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $18.20 |
| AVG Volume (30 Days) | 92.0K | ★ 1.4M |
| Earning Date | 01-27-2026 | 11-12-2025 |
| Dividend Yield | ★ 2.98% | N/A |
| EPS Growth | N/A | N/A |
| EPS | 0.34 | ★ 1.29 |
| Revenue | ★ $138,816,000.00 | $400,000.00 |
| Revenue This Year | $13.75 | N/A |
| Revenue Next Year | $35.05 | $1,590.36 |
| P/E Ratio | $39.52 | ★ $3.97 |
| Revenue Growth | ★ 33.08 | N/A |
| 52 Week Low | $7.59 | $3.93 |
| 52 Week High | $13.88 | $7.54 |
| Indicator | FRST | ABEO |
|---|---|---|
| Relative Strength Index (RSI) | 75.32 | 52.83 |
| Support Level | $13.23 | $4.80 |
| Resistance Level | $13.53 | $5.61 |
| Average True Range (ATR) | 0.37 | 0.25 |
| MACD | 0.13 | 0.00 |
| Stochastic Oscillator | 82.58 | 51.63 |
Primis Financial Corp is the bank holding company for Primis Bank, providing financial services to individuals and small and medium-sized businesses. Primis Bank offers a wide range of commercial banking services, It focuses on making loans secured mainly by commercial real estate and other types of secured and unsecured commercial loans to small and medium-sized businesses in several industries, as well as loans to individuals for a variety of purposes. Primis Bank offers a broad range of deposit products, including checking (NOW), savings, money market accounts, and certificates of deposit. Its operating segments are Primis Mortgage, Primis Bank, and Other.
Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company. The firm is focused on developing gene therapies and plasma-based products for life-threatening rare genetic diseases. Its clinical programs consist of pz-cel, an autologous, engineered cell therapy currently in development for recessive dystrophic epidermolysis bullosa (RDEB). The Company's development portfolio also features adeno-associated virus (AAV)-based gene therapies designed to treat unmet, medically needed ophthalmic diseases using the novel.